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1. Introduction 
Cerebral ischemia remains the main cause of adult disability in Western countries. More 
than 50% of stroke survivors are left with a motor disability, causing a huge burden for 
patients, relatives and healthcare systems (Bonita et al., 1997). Cell-based therapies have 
emerged as some of the most promising experimental approaches to restore brain function 
after stroke (Bliss et al., 2010; Banerjee et al., 2011; Lindvall & Kokaia, 2011). A wide variety 
of cell types have been studied, such as neural progenitors from different sources, including 
bone marrow- and blood-derived stem cells. Preclinical data with cell therapies are 
promising (Bliss et al., 2007; Hicks & Jolkkonen, 2009; Hicks et al., 2009a; Janowski et al., 
2010). The understanding of how transplanted cells exert their therapeutic effect is, 
however, not clear, but it is believed that the positive outcome is due to paracrine effects 
with an improved protective cellular environment (e.g., reduced inflammation, 
neuroprotection, reduced apoptosis, activation of endogenous repair) rather than as a 
consequence of neuronal differentiation and cell replacement (Zhang & Chopp, 2009).  
The robust therapeutic effect shown in the majority of preclinical studies is somewhat 
surprising given that cell preparations, experimental models and outcome measures have 
varied greatly (Table 1). More work is definitely needed to establish standard treatment 
protocols, which in turn should be expected to lead to effective translation of experimental 
data. The recently published STEPS guidelines are one step forward to guide future cell-
based research in stroke (STEPS Participant, 2009; Savitz et al., 2011). In addition to 
preclinical recommendations, guidelines on designing early-stage clinical trials are included.  
The first patient studies have shown the safety and feasibility of systemic cell therapy, but 
only marginal therapeutic benefit has so far been observed (Bang et al., 2005; Battistella et 
al., 2011; Honmou et al., 2011). Whether this is related to the type of cells, study design or 
low engraftment of the delivered cells is not known. This review provides an update of the 
current progress in intravascular cell therapy in stroke with a particular emphasis on 
strategies of how to improve the therapeutic effects. 
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Stroke model tMCAO, pMCAO, endothelin-1, cortical 
photothrombosis, hypoxia-ischemia 
Species rats, mice
Cell type rat/mouse/human cells from BM, UCB or 
adipose tissue, neural cells, genetically 
modified cells
Delivery route intravenous (tail vein, femoral vein), intra-
arterial (common carotid artery, internal 
carotid artery, external carotid artery) 
Delivery time 30 min - 1 month after the ischemic event 
Outcome measures histology (e.g., MAB1248), behavioral 
testing (e.g. sensorimotor, cognitive), 
imaging (e.g. MRI, SPECT, optical imaging) 
BM – bone marrow; MRI – magnetic resonance imaging; UCB – umbilical cord blood; SPECT – single 
photon emission computed tomography; tMCAO – transient middle cerebral artery occlusion;  
pMCAO – permanent middle cerebral artery occlusion 
Table 1. Variables with cell-based therapy in experimental stroke 
2. Special challenges in intravascular cell therapy in stroke 
Cell-based therapy after massive ischemic damage in stroke patients can be challenging 
compared to diabetes or Parkinson's disease, in which a restricted population of cells is lost. 
Not only neurons, but also glial cells and blood vessels need to be repaired. Severe odema 
and vascular compression associated with ischemic damage may limit the engraftment of 
cells, particularly in areas adjacent to infarct. Another distinction is that stroke is an acute 
injury with little or no degenerative process. Appropriate transplantable cells may not be 
immediately available for such an emergency. In addition, while early cell transplantation 
may provide neuroprotection, the hostile environment endangers the long-term survival of 
transplanted cells. Transplantation at later time points may be more realistic, targeting 
secondary neurodegeneration and promoting enhancement of the brain’s own repair 
mechanisms (Zhang & Chopp, 2009). Although cell survival may be preferable, scar 
formation and a lack of functional vasculature may limit the therapeutic benefit. The 
advantage is, however, that cell transplantation can be combined with other rehabilitative 
treatments to ensure maximal therapeutic benefit (Hicks et al., 2009b).  
Efficient cell delivery and an optimal delivery route are the keys to successful clinical 
outcomes, especially in all novel forms of cell therapy. Optimal cell delivery will be 
indication-dependent and local transplantation has until now been considered as the 
primary choice for regenerative tissue treatments. Systemic introduction should, however, 
be the ultimate goal for cell therapy, enabling rapid off-the-shelf therapy in any clinic and 
this would also allow less invasive treatments. Both stereotactic transplantation of cells into 
the brain and systemic delivery have been applied in experimental stroke (Guzman et al., 
2008; Hicks & Jolkkonen, 2009). Given that stroke often produces large ischemic damage, it 
is not known whether a targeted approach can provide efficient and extensive cell 
engraftment, even with the aid of anatomical and functional imaging to explore the location 
of cell transplantation. Another concern is the invasive nature of intracerebral 
transplantation. In contrast, the systemic introduction is minimally invasive and thus 
perhaps more easily applied in the clinic.  
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There are, however, some obstacles in the intravenous delivery route for cellular therapeutics, 
one of the main ones being massive lung adhesion, which has been observed after intravenous 
injection (Allers et al., 2004; Barbash et al., 2003; Fischer et al., 2009; Gao et al., 2001; 
Hakkarainen et al., 2007; Kang et al., 2006; Mäkinen et al., 2006; Meyerrose et al., 2007; Nystedt 
et al., 2006; Schrepfer et al., 2007; Tolar et al., 2006; Vilalta et al., 2008). In addition to the 
negative impact this has on the possibility of reaching clinically relevant cell numbers in target 
organs, lung entrapment of mesenchymal stem cells (MSC) has also been observed causing 
severe lung damage in mouse models (Anjos-Afonso et al., 2004; Lee et al., 2009a). 
Importantly, pulmonary toxicity is reported as one of the most common non-hematological 
complications after autologous bone marrow transplantation in humans, a complication that is 
also detectable in a mouse model (Bhalla & Folz, 2002). Interestingly, and on the contrary, 
beneficial effects have been found after MSC lung entrapment, where embolized human MSCs 
improved myocardial infarction in mice through secreting the anti-inflammatory protein 
tumour factor-stimulated gene-6 (TSG-6) (Lee et al., 2009b).  
3. Cell types used in stroke 
Stem cells are defined as undifferentiated cells capable of self-renewal and differentiation. 
Truly totipotent stem cells can only be found in the embryo and these are capable of 
producing a new individual upon implantation. Depending on their origin, stem cells are 
classified as pluripotent (i.e., embryonic) or multipotent (i.e., fetal and adult) stem cells, 
referring also to their differentiation capacity. Intracerebral transplantation is the primary 
delivery route for embryonic stem cells (ESC), induced pluripotent stem cells and fetal stem 
cells in experimental stroke. Thus only intravascular delivery of adult stem/progenitor cells 
and genetically modified cells will be discussed in the following chapters. 
3.1 Adult stem/progenitor cells 
The majority of systemic transplantation studies in stroke have used non-neural cells; cells 
from bone marrow (BM), umbilical cord blood (UCB), adipose tissue, or peripheral blood. 
These are all typically defined as adult stem/progenitor cells and represent a group of 
heterogeneous cell types. Usually many cell types are present in the population, such as 
mesenchymal stem/stromal cells, hematopoietic progenitors and endothelial progenitors, as 
well as more mature cell types (Erices et al., 2000; Herzog et al., 2003; Harris et al., 2008). 
Typically either the whole cell population has been used or a subpopulation has been 
selected with, e.g., cell surface markers or culture conditions (like adherent MSCs). Adult 
stem cells lack the ethical controversies associated with embryonic or fetal cells and they are 
rather easily obtained from different clinical sources.  
Different adult stem/progenitor cell populations have been reported to enhance functional 
recovery in experimental stroke models. When considering studies using human cells, 
mostly bone marrow stem/stromal cells (BM-MSC) (Li et al., 2002; Zhao et al., 2002; Chen et 
al., 2003; Zhang et al., 2004; Omori et al., 2008; Andrews et al., 2008; Mays et al., 2010; Yang 
et al., 2010; Bao et al., 2011) or UCBCs (Chen et al., 2001; Willing et al., 2003a; Borlongan et 
al., 2004; Vendrame et al., 2004; Xiao et al., 2005; Newcomb et al., 2006; Chen et al., 2006; 
Mäkinen et al., 2006; Zhang et al., 2011; Riegelsberger et al., 2011) have been used. Most 
studies have administered cells early (6-48 h) or at subacute phase (2-7 days) after stroke 
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and only few comparisons have been made. Omori et al. (2008) compared multiple time 
points and found that the greatest functional benefit was achieved when BM-MSCs were 
injected 6 h after stroke compared to later time points, which is supported by the finding of 
Yang et al. (2010) that cells delivered 1 day have greater effect than those at 7 days. Instead, 
Mays et al. (2010) reported time window from 1 to 7 days post-stroke to be equally 
beneficial. For UCBCs, time window up to 30 days post-stroke was found to be 
therapeutically beneficial (Zhang et al., 2011). 
In addition to BM and UCB cells, peripheral blood progenitor cells (Willing et al., 2003b), 
endothelial progenitors (Fan et al., 2010; Moubarik et al., 2011), CD34-positive progenitors 
from UCB (Taguchi et al., 2004; Boltze et al., 2005; Nystedt et al., 2006), CD133-positive cells 
from BM (Borlongan et al., 2005; Bakondi et al., 2009), as well as MSCs from placenta (Kranz 
et al., 2010) have provided therapeutic benefit in stroke. Also in these studies mostly early 
administration has been employed. For CD133 cells, delayed administration (7 d) was 
shown to improve graft survival but behavioral improvement was only apparent in 
immediate intravenous delivery (Borlongan et al., 2005). 
MSCs from BM or UCB (or other tissues) are a particularly promising candidate for cell 
therapy in stroke. MSCs are defined as multipotent stem cells that are adherent and express 
CD73, CD90 and CD105. They show the potential to differentiate into bone, cartilage and fat, 
and also exhibit additional differentiation capacity (Dominici et al., 2006). MSCs can be 
highly expanded in culture with a minimal loss of multipotency and they show very little 
immunogenic activity. This is a major advantage, allowing them to be potentially used as 
allogeneic "off-the-shelf" products. They have already been explored in many experimental 
models and clinical trials for their beneficial effects to, e.g., regenerate damaged tissue, treat 
adverse immune reactions, promote angiogenesis, and increase tissue protection, and MSCs 
are generally considered safe (Malgieri et al., 2010). 
Adult stem cells are particularly well suited for non-invasive vascular delivery, since they 
have been shown to target injured tissue and exert their therapeutic effect through secreted 
factors (Karp & Teo, 2008; Hess & Hill, 2011). The targeting of cells to the brain and 
especially their survival in situ have proven challenging, as in most studies very few cells 
are actually found in the brain. Interestingly, however, this may not be crucial, as 
intravenously administered cells may have a therapeutic effect on the brain by acting from 
peripheral organs as well, such as the spleen and the lung (Hess & Hill, 2011).  
As a summary, adult stem cells have been shown to exert their positive effect through 
soluble factors that reduce apoptosis and promote neuroprotection, angiogenesis, brain 
plasticity, and/or endogenous progenitor proliferation. Some studies have shown 
differentiation towards neuronal phenotype, but the significance of this remains unclear. 
3.2 Genetically modified cells 
In addition to stem cells, several neural cell lines have been reported to enhance functional 
recovery after experimental stroke by intravenous delivery of cells (Jeong et al., 2003; Chu et 
al., 2004; Lee et al., 2008; Narantuya et al., 2010). These cell lines are immortalised and thus 
have the advantage of unlimited expansion in culture. However, there is a potential risk of 
malignant transformation (Newman et al., 2005).  
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One approach has been to use immortalised human MSCs to, e.g., expand the limited life-
span of MSCs or include a gene for efficient in vivo tracking of cells. These cells have also 
shown positive effects in experimental stroke models when delivered intravenously 
(Honma et al., 2006; Wakabayashi et al., 2010). A critical aspect with these cells is that they 
should not lose their MSC phenotype upon modification. 
Human BM-MSCs have also been genetically modified to express neuroprotective/ 
angiogenic growth factors, such as brain derived neurotrophic factor (BDNF) (Kurozumi et 
al., 2004; Nomura et al., 2005), placental growth factor (PlGF) (Liu et al., 2006), glial cell line-
derived neurotrophic factor (GDNF) (Horita et al., 2006), erythropoietin (Cho et al., 2010), 
and vascular endothelial growth factor (VEGF) combined with angiopoietin-1 (Toyama et 
al., 2009). All these modified MSCs have shown their ability to improve functional recovery 
in ischemic rats, compared to unmodified MSCs, when delivered intravenously. GDNF-
modified human UCB CD34+ cells have also shown similar positive effects in vivo 
supporting the combined gene and stem cell therapy for the treatment of stroke (Ou et al., 
2010).  
4. Cell modifications that improve the efficiency of cell therapy 
The major problem with intravenous delivery is cell trapping within organs that filter the 
bloodstream. Previous studies have explored different strategies to minimize lung adhesion 
and improve homing of systemically introduced cells: use of vasodilators (Schrepfer et al., 
2007), pre-bolus injection of MSCs (Fischer et al., 2009), reducing the number of injected cells 
(Lee et al., 2009b), blockade of 6 and 4 integrins (Bonig et al., 2007; Qian et al., 2006; Bonig 
et al., 2009; Fischer et al., 2009), heparin saturation of MSCs (Deak et al., 2010) or 
preincubation of cells with white blood cells (Chute, 2006). Some beneficial effects on lung 
adhesion have been concluded, but the major mechanism behind this profound 
phenomenon is still unsolved. Interestingly, glycosylation engineering of stem cell surfaces 
by enzymatic ex vivo cell surface fucosylation has improved the homing and engraftment 
capacity of cord blood-derived cells (Xia et al., 2004) and, interestingly, the homing of BM-
MSCs to the bone marrow (Sackstein et al., 2008). One feasible approach to alter cell surface 
structures and migratory behavior is also through culture conditions. A recent preclinical 
study has shown that low passage and low-density cultures of BM-MSCs impact cell 
structures that favour in vivo targeting to the infarcted heart (Lee et al., 2009a). Culturing 
MSCs in low oxygen increases the levels of relevant cell surface chemokine and growth 
factor receptors, subsequently increasing the in vitro migratory behavior and the therapeutic 
potential of MSCs (Hung et al., 2007; Rosova et al., 2008). Cells are normally maintained in a 
20% O2 tension in culture, but a lower oxygen tension in culture is more akin to the 
physiological niche for the MSC in the bone marrow or placenta (2-7% O2) and would 
facilitate in maintaining the authentic in vivo identity of the MSCs. Culturing MSCs without 
animal-derived reagents can produce beneficial changes in expression levels of important 
adhesion receptors and the secretion potential of trophic mediators, which might have an 
important impact on cell migratory behavior and therapeutic potential. To support this, 
Bieback et al. (2009) recently showed differential expression of the fibronectin receptor CD29 
between MSCs cultured in fetal bovine serum versus human blood components. The impact 
of MSC xenofree culture conditions have not yet been studied or reported in preclinical 
stroke models.  
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5. Effect of administration route 
The most effective transplantation route to deliver cells into the brain following cerebral 
ischemia remains to be addressed. Noninvasive intravascular administration of cells has 
perhaps the most immediate access for clinical applications. It provides a broad distribution 
of cells in close proximity to ischemic tissue, although the entry of intravenously injected 
cells into the central nervous system may not be required for therapeutic effects (Borlongan 
et al. 2004). However, a reliable estimation of cell numbers in the brain in relation to other 
organs is lacking.  
Modern imaging methods such as single photon emission computed tomography (SPECT), 
positron emission computed tomography (PET), magnetic resonance imaging (MRI) or 
optical imaging can be used for the in vivo tracking of cells. Excellent reviews on the 
different imaging modalities are available (Sykova & Jendelova, 2007; Gera et al., 2010). 
SPECT imaging with indium oxine (111In-oxine) offers an efficient method to study the 
whole body biodistribution of cells in stroke models (Figure 1). Firstly, the labeling of the 
cells is straightforward and relatively simple without significant loss of cell viability. The 
most common labels are 111In-oxine or technetium-hexamethylpropyleneamine oxime 
(99mTc-HMPAO). Double labeling with 111In and 131I or 18F- fluorodeoxyglucose (FDG) and 
111In is also possible (Blocklet et al., 2006; Stodilka et al., 2006). Secondly, the half-life of 111In 
is optimal for several days follow-up after a single injection. Additional advantages of 
SPECT include high sensitivity, short scanning times (<5 min), and possible multimodal 
imaging (MRI, CT) with the same stereotaxic coordinates. More importantly, whole-body 
imaging provides an estimation of the proportion of injected cells that eventually enter the 
brain in relation to other organs, to help in the assessment of the functional value of 
transplantation. SPECT imaging is also truly translational and the same tracers can be used 
in human studies (Correa et al., 2007; Barbosa da Fonseca et al., 2010).  
 
Fig. 1. Combined SPECT/CT images of 111In-oxine labeled human bone marrow-derived 
mesenchymal stem cells (BM-MSCs) in a rat subjected to middle cerebral artery occlusion 
(MCAO). Images are taken 20 min (A) and 24 h (B) after intra-arterial administration of cells 
(4 × 105 cells; 3 MBq) 24 h after MCAO surgery. Please note the initial high signal in the 
brain followed by relocation of cells into the internal organs. A minor signal remains in the 
ischemic hemisphere.  
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Several studies have compared different administration routes. Willing et al. (2003a) 
concluded that intravenous administration of human UCBCs may be more effective that 
intracerebral transplantation. 111In–oxine labeled human UCBCs have, however, been shown 
to localize primarily to the internal organs post intravenous injection in rats after middle 
cerebral artery occlusion (MCAO) (Mäkinen et al., 2006). Chen and co-workers also showed 
that after intravenous administration of human UCBCs in MCAO rats, only 1% of injected 
cells were detected in the brain (Chen et al., 2001). Undesirable biodistribution is most likely 
caused by the accumulation of cells in the trapping and filtering organs such as the lung, 
liver, and spleen, rather than due to the cell type injected or timing of administration. Thus, 
intra-arterial cell infusion may be a more efficient route to circumvent trapping in the 
internal organs and to target cells towards the ischemic brain (Lappalainen et al., 2008; 
Walczak et al., 2008; Li et al., 2010; Chua et al., 2011). Indeed, intra-arterial infusion resulted 
in minor engraftment of human ESCs into the ischemic hemisphere while no SPECT signal 
was detected after intravenous infusion (Lappalainen et al., 2008). Walczak et al. (2008) 
compared intravenous and intra-arterial delivery of MSCs in MCAO rats by using combined 
laser Doppler blood flow monitoring and MRI of iron labeled cells. The intra-arterial but not 
intravenous cell injection was shown to provide successful but variable cerebral 
engraftment, which was possibly due to microvascular occlusions. Engraftment was 
associated with high morbidity as also confirmed by Li et al. (2010). Later, it was shown that 
a modified injection technique with preserved flow in the carotid artery prevented decrease 
in cerebral blood flow and micro-occlusions (Chua et al., 2011). Intra-arterial over 
intravenous administration is also supported by the transplantation of mouse neural stem 
cells in a hypoxia-ischemia mouse model (Pendharkar et al., 2010). More importantly, a 
sustained presence (2 weeks) of transplanted cells in the brain was observed after intra-
arterial administration. However, recently both intravenous and intra-arterial routes were 
shown to equally improve neurological recovery and provide neuroprotection (Gutierrez-
Fernandez et al., 2011). In all above-mentioned studies, cell were administered within 24-48 
h of ischemia. 
Taken together, the delivery route seems to have an impact on the biodistribution of 
transplanted cells. Intra-arterial administration provides superior delivery of cells to the 
ischemic brain, although this depends on the type of cells and the experimental model 
employed. 
6. Effective dose and therapeutic time window for cell transplantation 
The effective cell dose needed for therapeutic effects in stroke animals is not well known. 
Intravenous infusion of 104 up to 5 x 107 human UCBCs improved behavioral deficits in 
MCAO rats in a dose-dependent manner, when administered at 24 h of ischemia (Vendrame 
et al., 2004). A dose of 106 cells was the threshold to promote functional recovery. Similarly, 
human umbilical tissue-derived cells at doses more than 3 x 106 have improved the 
behavioral outcome and enhanced several brain repair mechanisms (Zhang et al., 2011). A 
meta-analysis of 60 preclinical studies also found a dose-response association between the 
injected cell number and treatment effects (Janowski et al., 2010). Interestingly, the greatest 
therapeutic benefit is achieved following a single high cell dose injection of human MSCs 
(3.0 x 106) within 6 h of ischemia rather than multiple low dose injections (Omori et al., 
2008). Thus, repeated dosing may not provide additional benefit. While the dose in 
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preclinical studies is established to be around 106 cells per animal, it is more complicated to 
estimate the optimal dose for clinical studies. Dosing should be based on a dose-response 
curve and a maximum tolerated dose, as suggested by STEPS recommendations (STEPS 
Participant, 2009). The doses in early phase clinical trials were scaled to body weight and 
have varied from 5 x 107 (twice) (Bang et al., 2005) to 0.5 - 5 x 108 (Honmou et al., 2011) per 
patient.  
In most of the experimental studies (67%), cells were given <24 h after ischemia (Hicks et al., 
2009a). This is partly because of the opening of the blood-brain barrier after cerebral ischemia, 
which allows cells to enter the brain parenchyma (Belayev et al., 1996). Also, the expression of 
various chemotactic signals peaks at this time point and guides the cells towards ischemic 
areas (Imitola et al., 2004; Wang et al., 2008). However, while early cell transplantation may 
provide neuroprotection (Homna et al., 2006; Horita et al., 2006), the hostile environment 
endangers the long-term survival of transplanted cells. Transplantation at later time points 
may target against secondary neurodegeneration and promote enhancement of the brain’s 
own repair mechanisms (Zhang & Chopp, 2009). Komatsu et al. (2010) showed that MCAO 
rats receiving MSCs up to 1 month after ischemia showed enhanced functional recovery and 
associated angiogenesis in cortical areas adjacent to the infarct. Shen et al. (2007) have also 
showed that cell transplantation 1 month after MCAO is effective by leading to long-lasting 
behavioral improvement. Behavioral and morphological evidence suggest that the post-stroke 
brain displays heightened sensitivity to rehabilitative treatment early after the stroke (1 wk), 
but declines with time (2-4 wk) (Biernaskie et al., 2004). Based on this, the time of cell 
transplantation could be extended to up to 7 days after ischemia.  
7. Clinical perspectives and future directions of intravascular cell therapy for 
stroke 
Promising experimental data have prompted early phase I/II patient studies. In these 
studies, either bone marrow mononuclear cells or bone marrow-derived mesenchymal stem 
cells have been used. Three phase I studies explored the use of bone marrow mononuclear 
(BM-MNC) cells for stroke (Barbosa da Fonseca et al., 2010; Battistella et al., 2011; Suarez-
Monteagudo et al., 2009). The most important finding of these studies is that intra-arterial 
delivery of mononuclear cells directly to the infarcted hemisphere is safe. Interestingly, 
Barbosa da Fonseca et al. (2010) labeled the mononuclear cells with technetium-99m, and 
followed the distribution of the cells in six stroke patients. They were able to show that the 
cells remained at the site of the lesion for two hours, but then the signal disappeared on all 
but two patients after 24 hours. It is unclear whether this short time of action will be enough 
for any therapeutic benefit. 
Bang and co-workers pioneered in the use of MSCs for ischemic stroke with two studies 
(Bang et al., 2005; Lee et al., 2010). In the first one, five patients with stroke received 
autologous MSCs as two intravenous infusions of 5 x 107 cells each. The outcome of the 
patients after one year was compared to 25 randomized controls in an open-label study. The 
second study followed the same protocol as the first one but included 16 patients and 36 
controls, and the patients were followed for five years. Both studies concluded that 
intravenous infusion of MSCs in stroke patients was safe. There was no apparent increase in 
mortality, bovine spongiform encephalitis or other zoonoses, arrhythmias, seizures, or 
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tumors. The true incidence of possible side effects of MSC therapy can, however, only be 
evaluated after much larger patient groups have been treated and followed. Interestingly, 
patients showed significant improvement in the Barthel Index (BI) in both studies, and a 
trend towards improvement in the modified Rankin Scale (mRS) in the first study. There 
was some concern as to whether the improved functional recovery was upheld with time 
(Bang et al., 2005), but later this was confirmed as improvement could still be measured at 
3.5 years (Lee et al., 2010). Because of the time required to produce the autologous 
therapeutic cells used, the infusion of the cells occurred rather late, i.e. the first cell infusion 
was given at weeks 4-5 and the subsequent one at weeks 7-9 after the onset of the stroke. 
Honmou and colleagues (2011) studied the safety and feasibility of intravenous infusion into 
stroke patients of autologous MSCs that had been expanded in autologous serum. The cells 
were infused 33-133 days post-stroke, and the patients were followed and imaged at one 
year after. No adverse events were recorded. 
Several important questions still need to be addressed in both preclinical and clinical testing. 
It is unclear which cell type is therapeutically the most beneficial. Both BM-MNCs and 
MSCs have shown promise in preclinical testing. Selecting the best route of therapeutic cell 
delivery is also a major issue. Presumably, the route yielding the most effective delivery of 
cells to the injured tissue might offer most therapeutic potential. In a recent study 
comparing intra-arterial and intravenous MSC delivery, infusion directly into the internal 
carotid artery resulted in more engrafted cells as well as a more widespread distribution of 
cells within the infarcted hemispheres of rats (Li et al. 2010). However, this mode of 
administration was also associated with high mortality as the MSCs were sequestered in the 
blood vessels of the treated hemisphere and formed micro-occlusions. Careful development 
of safe but effective modes of administration is required for the advancement of this 
technique towards the clinic. In contrast to MSCs, BM-MNCs can apparently be 
administered via the intra-arterial route without harmful effects.  
Another important question is the preferred timing of the cell infusion. There is some 
evidence suggesting that MSCs infused early (within days of the infarct) have more 
therapeutic efficacy than those administered several weeks after the event (Zhou et al., 
2011). Theoretical considerations support these findings: a major mode of action of the MSCs 
in stroke is attenuation of the post-infarct inflammatory milieu, which is at its strongest 
during the early days following the insult (Ohtaki et al., 2008). BM-MNCs have the 
advantage of having no need for cell expansion. Thus, the patient can be treated soon after 
stroke even if autologous cells are used. 
Whether the patient should be given autologous or allogeneic MSCs is a major unanswered 
question. If the patient is given autologous cells, the therapy will necessarily take place 
several weeks after the infarct due to the time required to produce the cells. Allogeneic cells 
offer the critical advantage of being available off-the-shelf. It can be argued that allogeneic 
cells are quickly rejected and will rapidly lose their therapeutic efficacy, but if only short 
term action is required e.g., to modulate post-infarct inflammation, allogeneic cells may be 
an ideal therapeutic vehicle. In experimental animals, allogeneic cells appear to function as 
equally well as autologous MSCs (Li et al., 2006). Furthermore, risks of tumor formation are 
reduced, because the allogeneic cells are eventually rejected by the host’s immune system 
(Poncelet et al., 2007).  
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Finally, the optimal characteristics of the therapeutic cells need to be determined. Special 
attention needs to be given to the conditions of cell production, because the administration 
of apoptotic or senescent cells is not only ineffective, but positively harmful (Modo et al., 
2003; Prockop et al., 2010). Another important advance will be the adoption of xenofree 
culture methods for MSCs, reducing the risks of anaphylaxis and transmission of diseases 
(Horwitz et al., 2002). Modification of the cell surface prior to administration, to improve the 
delivery or therapeutic efficacy of the cells, is a promising strategy.  
Taken together, there is already preliminary evidence for the safety of intravenously 
delivered BM-MNCs and MSCs for stroke patients. Further work is required to establish this 
safety profile. However, careful studies that also use an intra-arterial application of cells 
should proceed. Futhermore, the use of allogeneic MSCs should be explored, allowing 
treatment during the first week after infarct. 
Currently, eight clinical phase I-II studies are underway, assessing the safety and possible 
efficacy of either fractionated BM cells or culture-expanded MSCs in patients with recent 
ischemic stroke (Table 2). Three studies will address the feasibility and safety of intravenous  
Identifier/Sponsor* Cell type Time 
window
Adminis-
tration route
Comments  
NCT00859014/The 
University of Texas 
Health Science Center, 
Houston, USA 
autologous BM-MNCs 24-72 h i.v. phase I, non-
randomized 
NCT01028794 National 
Cardiovascular Center, 
Japan 
autologous BM-MNCs day 7-10 i.v. phase I-II, non-
randomized 
NCT00473057/Federal 
University of Rio de 
Janeiro, Brazil 
autologous BM-MNCs day 3 - 90 
 
i.v./i.a. phase I, 
completed 
NCT761982/Hospital 
Universitario Central de 
Asturias, Spain 
autologous BM CD34+ 
cells 
day 5-9 i.a. phase I-II, non-
randomized, 
completed 
NCT01273337/Aldagen, 
USA 
autologous BM ALDH-
positive cells
day 13-19 i.a. phase II, 
randomized   
NCT01297413/Stemedica 
Cell Technologies Inc, 
USA 
allogeneic MSCs > 6 mo i.v. phase I-II, non-
randomized 
NCT00875654/ 
University Hospital, 
Grenoble, France 
autologous MSCs within 
6 wks 
i.v. phase II, 
randomized 
trial 
NCT01389453/General 
Hospital of Chinese 
Armed Police Forces; 
China 
allogeneic cord blood 
MSCs 
day 7-14 i.v. phase I, non-
randomized 
*from www.clinicaltrials.com  
Table 2. Summary of ongoing clinical trials with intravascular administration of cell therapy 
in stroke. Only recruiting or completed studies are listed. 
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BM-MNCs, and one of these will compare intravenous with intra-arterial delivery. Two 
more trials will utilize BM cells that have been selected using stem cell markers (CD34 or 
aldehyde dehydrogenase). Three studies evaluate the use of MSCs for stroke, one of them 
using the patients’ own and two using allogeneic cells. In most of these early studies, cells 
will be administered via the intravenous route. These studies, and others addressing the 
questions posed above, may help us in ameliorating the devastating consequences of 
ischemic stroke at the personal and societal level. 
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